By David Bautz, PhD
NASDAQ: IMNN
READ THE FULL IMNN RESEARCH REPORT
Business Update
Fully Focused on Rapidly Advancing OVATION 3 Trial
Imunon, Inc. (NASDAQ: IMNN) is currently conducting the Phase 3 OVATION 3 trial of IMNN-001 in women with newly diagnosed advanced ovarian cancer, and it remains the company’s top priority. The trial is designed to confirm the overall survival benefit observed in the Phase 2 OVATION 2 Study (see below). In February 2026, the company announced a strategic reorganization to concentrate resources on trial execution, including eliminating non-essential roles and redefining responsibilities to support enrollment and site expansion. Management recently indicated that trial enrollment is ahead of schedule, which we believe is the result of strong interest and support from clinicians and patients excited by the prospect of an improvement in the standard of care for a disease that has not seen appreciable advancements in over 30 years.
The trial has been designed to prioritize the enrollment of women positive for homologous recombination deficiency (HRD+) and has two interim analyses at 50% and 75% of events. This will help the company conserve cash while targeting the highest probability subgroup to deliver results as quickly as possible. The trial has 98% power to detect a statistically significant increase in overall survival in the HRD+ population, with a probability for stopping early for success at the interim readout of >90%.
Updated OVATION 2 Data Shows Continued Improvement in OS
On March 25, 2026, Imunon announced updated data from the Phase 2 OVATION 2 trial of IMNN-001 in women with newly diagnosed ovarian cancer. The OVATION 2 trial evaluated IMNN-001 in combination with standard of care (SoC) neoadjuvant and adjuvant chemotherapy in 112 women with newly diagnosed advanced ovarian cancer. Previously, the company had reported an 11.1-month increase in overall survival (OS) (40.5 vs. 29.4 months) in the IMNN-001 treatment arm compared to SoC chemotherapy alone. The updated data shows a median 14.7-month increase in OS (45.1 vs. 30.4 months) in women in the IMNN-001 treatment arm compared to SoC chemotherapy. In addition, for women being treated with IMNN-001, SoC chemotherapy, and poly ADP-ribose polymerase (PARP) inhibitors, the increase in median OS is now 24.2 months (65.6 vs. 41.4 months) compared to SoC chemotherapy and PARP inhibitors.
These results continue to show the positive impact that IMNN-001 is having on patients with newly diagnosed advanced ovarian cancer. There have been few notable advancements in the SoC for ovarian cancer in the past 30+ years, thus the now 14.7-month increase in OS, if it can be replicated in the ongoing Phase 3 OVATION 3 trial, could lead to a paradigm shift in how these patients are treated. Lastly, the increase in OS was accomplished with a favorable safety and tolerability profile and is another reason why IMNN-001 has received such a positive response from the medical community.
Financial Update
On March 31, 2026, Imunon announced financial results for the year ending December 31, 2025. As expected, the company did not report any revenues in 2025. R&D expenses in 2025 were $7.8 million, compared to $11.6 million in 2024. The decrease was due primarily to lower costs associated with the OVATION 2 study, the Phase 1 proof-of-concept PlaCCine DNA vaccine trial, and development of the PlaCCine DNA vaccine technology platform. G&A expenses were $6.9 million in 2025 compared to $7.5 million in 2024. The decrease was primarily due to headcount reductions and lower employee-related expenses.
Imunon exited 2025 with $8.8 million in cash and cash equivalents, which we estimate is sufficient to finance operations into the second half of 2026. As of March 30, 2026, the company had 3.9 million common shares outstanding and, when factoring in stock options and warrants, a fully diluted share count of approximately 8.6 million.
Conclusion
The increase in OS for the OVATION 2 trial adds to the already robust data set that Imunon has accumulated on IMNN-001, showing its positive impact in the treatment of advanced ovarian cancer. The company is continuing its full focus on the OVATION 3 and anticipates having the trial approximately 20% enrolled within the next year. We look forward to additional updates from the company this year on additional trial sites being opened for the OVATION 3 trial, which may increase the rate of enrollment further. With no changes to our model, our valuation remains at $33 per share.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.